TruCan Ultra CIV: bivalent vaccine offers new perspective in canine influenza prevention.

Introduction
Canine influenza—caused by H3N2 and H3N8—can severely impact social dogs and kennels. With USDA approval for Elanco's TruCan Ultra CIV, a bivalent weapon is now available that covers both strains.

Why bivalent?
Previous vaccines often targeted one strain, allowing outbreaks caused by the other strain to persist. TruCan Ultra CIV combines antigens from both strains, leading to broad immunity and reduced viral shedding in clinical trials.

Clinical results
• 95% of vaccinated dogs showed sufficient antibody response
• 80% fewer symptoms when exposed under test conditions
• No serious side effects reported

Application in practice
Veterinarians now recommend routine vaccination for puppies from 6 weeks of age and booster doses for kennels with intensive contact. This helps:

• Protecting vulnerable breeds , such as brachycephalic dogs.
• Preventing kennel outbreaks that lead to high healthcare costs.
• Reducing public health care burden in case of complications.

Economic impact
Elanco reacted positively on the stock market, with a share price increase of 1.5%. For owners, this means one-time cost savings due to fewer sick days and hospital stays.

Advice for owners

1. Discuss vaccination schedule with your veterinarian.
2. Combine with hygiene in kennels and during shows.
3. Monitor recovery closely after vaccination.

Conclusion
TruCan Ultra CIV sets the standard for modern canine influenza vaccines. With broad protection and high safety, it gives owners and veterinarians the confidence to effectively control outbreaks—and keep dogs healthy.